Table 2.

Statin prescription based on ACC/AHA eligibility groups for primary prevention

Variable	Eligible Patients	Statin Prescribed	High* Intensity Statin	Moderate† Intensity Statin	Women Prescribed Statin	Men Prescribed Statin	P value
LDL ≥190 mg/dL‡	194	112 (57.7%)	65 (58.0%)	44 (39.2%)	92/152 (60.5%)	20/42 (47.6%)	0.14
Diabetes mellitus†	2751	2024 (73.6%)	1070 (52.9%)	871 (43.0%)	1273/1778 (71.6%)	751/973 (77.2%)	0.001
ASCVD risk ≥ 20%§	1270	769 (60.6%)	359 (46.7%)	360 (46.8%)	440/720 (61.1%)	329/550 (59.8%)	0.64
ASCVD risk ≥ 7.5% & < 20%§	2891	1006 (34.8%)	383 (38.1%)	565 (56.2%)	688/1954 (35.2%)	318/937 (33.9%)	0.50
Without RE∥	1899	600 (31.6%)	226 (37.7%)	335 (55.8%)	393/1249 (31.5%)	207/650 (31.8%)
With RE∥	992	406 (40.9%)	157 (38.7%)	232 (57.1%)	295/705 (41.8%)	111/287 (38.7%)
ASCVD risk ≥ 5% & < 7.5%‡ with RE∥	444	83 (18.7%)	27 (32.5%)	47 (56.6%)	70/352 (19.9%)	13/92 (14.1%)	0.21
Total	7550	3994	1904	1887	2563	1431

ACC = American College of Cardiology; AHA = American Heart Association; LDL = low-density lipoprotein; RE = risk enhancer; all other abbreviations as in Table 1.

^*High intensity statin: atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg.

^†Moderate intensity statin: atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, pravastatin 40 to 80 mg, lovastatin 40 mg, fluvastatin 80 or 40 mg BID, pitavastatin 3 to 4 mg.

^‡Inclusion: age 20 to 75. Inclusion: age 40 to 75, LDL ≥70 and <190 mg/100 ml, no DM.

^§Inclusion: age 40 to 75, LDL< 190 mg/100 ml.

^¶Risk enhancers included: family history of premature ASCVD, LDL ≥160, chronic kidney disease, inflammatory diseases, persistently elevated triglycerides ≥175, high sensitivity C-reactive protein ≥2.